evidence: Many of the initial clinical studies with COVID-19 vaccines have included a small number of people living with HIV (PLHIV) in their trials. Despite limited data, available information from those studies suggests that current WHO recommended COVID-19 vaccines are safe for PLHIV. The currently available COVID-19 vaccine products are not live vaccines but include modified viral proteins or genetic material from SARS-CoV-2 which cannot replicate or cause changes to human genes. More recent observational studies have further evaluated the safety of COVID-19 vaccines in this population and didn’t find any evidence of a higher rate of unusual side effects after vaccination when compared with general population. In addition, no pharmacological interactions have been reported between COVID-19 vaccines and antiretroviral medications (ARV) which [...] Despite these potential concerns, it is important to highlight that the benefits of all authorized COVID-19 vaccines in a pandemic context largely outweigh this potential risk. The theoretical concern on increased risk of HIV acquisition is confined to a specific Ad5 vectored HIV vaccine and should not be extended to other vaccine platforms. However, as several COVID-19 vaccines are using human and animal adenovirus vector platforms, specific studies are encouraged to better assess the safety of Ad5 vectored COVID-19 vaccines in sub-populations at high risk of HIV acquisition. An extended follow-up from a Phase III study of an Ad5 vectored COVID-19 vaccine is currently evaluating HIV seroconversion rates in the participants, and interim results are expected in the end of 2022.